Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

The Lancet. Gastroenterology & hepatology

DOI: 10.1016/s2468-1253(22)00348-x Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 6 stored of 336

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
2025 The Lancet Oncology article Medicine Pancreatic and Hepatic Oncology Research Open access

57

citations
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial
2025 Journal of Clinical Oncology article Medicine Pancreatic and Hepatic Oncology Research Open access

42

citations
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma
2025 JNCI Journal of the National Cancer Institute article Medicine Pancreatic and Hepatic Oncology Research Open access

3

citations
Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2)
2024 The American Journal of Surgical Pathology article Computer Science AI in cancer detection Open access

6

citations
Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer
2023 Gut article Medicine Pancreatic and Hepatic Oncology Research Open access

37

citations
Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care
2023 Cancers article Medicine Venous Thromboembolism Diagnosis and Management Open access

9

citations

6 results

References 3

3 results